Biogen Second Quarter 2015 Revenues Increase 7% to $2.6 Billion

Bernstein Upgrades Biogen (BIIB) to Outperform

Bernstein upgraded Biogen (NASDAQ: BIIB) from Market Perform to Outperform with a price target of $385.00 (from $436.00).

For an analyst ratings summary and ratings history on Biogen click here. For more ratings news on Biogen click here.

Shares of Biogen closed at $300.03 yesterday.

Baird Downgrades Biogen (BIIB) to Neutral; Diminished Growth Prospects

Baird downgraded Biogen (NASDAQ: BIIB) from Outperform to Neutral with a price target of $316.00 (from $480.00), saying lackluster sales and lowered guidance leaves a growth void.

Analyst Brian Skorney commented, "We're aware that this downgrade may be too little, too late given... More

Biogen's (BIIB) Decline Seen as 'Overreaction' at Deutsche Bank

Deutsche Bank maintained a Buy rating on Biogen (NASDAQ: BIIB) with a price target of $460. Shares declined after Biogen reported Q2 results and cut full-year guidance. In the view of analyst Robyn Karnauskas, the decline was an "overreaction," though she agrees with sentiment.

"The disappointing run of BIIB continued in Q215 as the co substantially revised 2015 FY guidance due to weaker outlook for Tecfidera.... More

Stocks Hit Session Lows; Biotech, Homebuilders Lead Slump

Stocks hit session lows Friday afternoon, with the S&P down 0.75% and the Nasdaq lower by 0.5% -- despite huge gains in Amazon.com (NASDAQ: AMZN).

Biotech was among the worst performing sectors with ETFs like iShares Nasdaq Biotechnology (NASDAQ:... More

Biogen (BIIB) Trading at 'Pharma-Like' Multiple, Cowen Says

Cowen analyst Eric Schmidt reiterated his Outperform rating and $494 price target on Biogen (NASDAQ: BIIB), with shares down nearly 20% on disappointing Q2 results and outlook. Schmidt maintained his bullish view, saying the stock is trading at a 'pharma-like' multiple.

Schmidt commented,... More

Biogen (BIIB) Worth a 'Hard Look' when Smoke Clears, Stifel Says

Stifel analyst Thomas Shrader weighed in on Biogen (NASDAQ: BIIB) following disappointing Q2 results, which has shares down 18.4% intra-day. While retaining his Hold rating, the analyst said the stock is worth a hard look when the smoke clears.

Shrader commented, "Biogens numbers were... More